Abstract OBJECTIVE: To investigate the feasibility, safety and clinical efficacy of early postoperative application of enteral nutrition (EN) in gastric tumor patients. METHODS: Gastric tumor patients with concomitant malnutrition were treated with early postoperative EN, and body weight (BW), body mass index (BMI), plasma albumin (Alb), prealbumin (PreA), transferrin (TFN), immunoglobulin, lymphocyte counts, C-reactive protein (CRP), hepatic and renal functions, gastrin (GAS), gastric actin (Motilin, MTL), and cholecystokinin (ChK) were measured before and after nutritional support, respectively, GAS), gastrin (Motilin, MTL), cholecystokinin (CCK) levels, and observed the patients’ vital signs, gastrointestinal function recovery status, gastrointestinal adverse reactions and surgical complications. RESULTS: None of the patients experienced serious adverse reactions during the study period, and all of them could safely tolerate early postoperative EN. Alb, PreA, immunoglobulin, cellular immune function, GAS, and MTL levels returned to normal on the 7th day after the operation, while the levels of TFN and CCK increased significantly compared with the preoperative levels. CONCLUSION: Early postoperative EN for gastric tumors is safe and reliable, which can improve the malnutrition status of patients at an early stage, improve the immune dysfunction caused by tumors and surgical trauma, and is conducive to the promotion and maintenance of gastrointestinal tract function.